Rheumatoid Arthritis(RA)is a common chronic inflammatory autoimmune disease characterized by progressive joint destruction.The elderly with RA consists of both elderly-onset RA(EORA)that manifests after the age of 60 and individuals diagnosed with RA early(YORA)in life who age naturally to become members of this group.With the progression of population aging,the incidence of EORA is on the rise annually.EORA typically occurs more frequent-ly in males and possesses distinct clinical features and laboratory findings.EORA often presents with an acute onset,pre-dominantly affecting large and proximal joints,and is associated with a lower positivity rate of rheumatoid factors.Addi-tionally,the increased clinical comorbidities in EORA patients pose additional challenges to treatment.The use of non-steroidal anti-inflammatory drugs in elderly patients carries a higher risk of side effects,while conventional synthetic dis-ease-modifying anti-rheumatic drugs have shown similar efficacy in both EORA and YORA patients.However,there is currently a lack of definitive research on the safety and effectiveness of biological disease-modifying anti-rheumatic drugs in EORA patients.Therefore,this study aims to provide a comprehensive overview of the epidemiology,clinical character-istics,comorbidities,and treatment approaches for EORA,offering a more holistic guide for its management.
维普
万方数据
